{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:22:47Z","timestamp":1790022167031,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"39","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.vaccine.2021.07.097","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T23:19:43Z","timestamp":1629847183000},"page":"5680-5687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Live attenuated vaccine efficacy six months after intravenous immunoglobulin therapy for Kawasaki disease"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1437-0374","authenticated-orcid":false,"given":"Yoshihiko","family":"Morikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3904-7087","authenticated-orcid":false,"given":"Hiroshi","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Kimiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimasa","family":"Obonai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.07.097_b0005","doi-asserted-by":"crossref","unstructured":"Recommended timing of routine measles immunization for children who have recently received immune globulin preparations. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics. 1994;93:682\u20135.","DOI":"10.1542\/peds.93.4.682"},{"key":"10.1016\/j.vaccine.2021.07.097_b0010","doi-asserted-by":"crossref","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","article-title":"Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association","volume":"135","author":"McCrindle","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2021.07.097_b0015","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1253\/circj.CJ-19-1094","article-title":"JCS\/JSCS 2020 Guideline on Diagnosis and Management of Cardiovascular Sequelae in Kawasaki Disease","volume":"84","author":"Fukazawa","year":"2020","journal-title":"Circ J"},{"key":"10.1016\/j.vaccine.2021.07.097_b0020","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1542\/peds.63.2.175","article-title":"Kawasaki disease: effect of treatment on coronary artery involvement","volume":"63","author":"Kato","year":"1979","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.07.097_b0025","doi-asserted-by":"crossref","unstructured":"Research Committee of the Japanese Society of Pediatric C, Cardiac Surgery Committee for Development of Guidelines for Medical Treatment of Acute Kawasaki D. Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version). Pediatr Int 2014;56:135\u201358.","DOI":"10.1111\/ped.12317"},{"key":"10.1016\/j.vaccine.2021.07.097_b0030","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/rheumatology\/key344","article-title":"European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease - the SHARE initiative","volume":"58","author":"de Graeff","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.vaccine.2021.07.097_b0035","unstructured":"Ezeanolue E, Harriman K, Hunter P, Kroger A, Pellegrini C. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). [www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/downloads\/general-recs.pdf]. Accessed on [2021\/8\/11]."},{"key":"10.1016\/j.vaccine.2021.07.097_b0040","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0022-3476(06)80114-9","article-title":"Interference of immune globulin with measles and rubella immunization","volume":"122","author":"Siber","year":"1993","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2021.07.097_b0045","first-page":"277","article-title":"Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases","volume":"6","author":"Kobrynski","year":"2012","journal-title":"Biologics"},{"key":"10.1016\/j.vaccine.2021.07.097_b0050","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1161\/01.CIR.0000079166.93475.5F","article-title":"Prognostic impact of vascular leakage in acute Kawasaki disease","volume":"108","author":"Terai","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2021.07.097_b0055","first-page":"1929","article-title":"Intravenous gamma-globulin therapy and vaccination (in Japanese)","volume":"26","author":"Sonobe","year":"1994","journal-title":"Shoni-naika"},{"key":"10.1016\/j.vaccine.2021.07.097_b0060","unstructured":"Sonobe T, Sakiyama Y, Furukawa S, Harada K, Yamaguchi H, Seki I, et al. Study of immunity in patients with Kawasaki disease after gamma-globulin therapy: measles antibody and vaccination. Report of research on handicapped patients by The Ministry of Health and Welfare in the Heisei 3 fiscal year: studies on total care of chronic diseases in children. 1991:39-42."},{"key":"10.1016\/j.vaccine.2021.07.097_b0065","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1086\/315111","article-title":"Kawasaki disease: a maturational defect in immune responsiveness","volume":"180","author":"Kuijpers","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.07.097_b0070","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.jaci.2013.01.045","article-title":"Reduced serologic response to mumps, measles, and rubella vaccination in patients treated with intravenous immunoglobulin for Kawasaki disease","volume":"131","author":"Tacke","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2021.07.097_b0075","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jama.1968.03150030043009","article-title":"Development and evaluation of the Moraten measles virus vaccine","volume":"206","author":"Hilleman","year":"1968","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.07.097_b0080","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/bmj.3.5925.221","article-title":"New Japanese rubella vaccine: comparative trials","volume":"3","author":"Best","year":"1974","journal-title":"Br Med J"},{"key":"10.1016\/j.vaccine.2021.07.097_b0085","unstructured":"Hirayama M, Kimura M, Kimura K, Kawakami K, Minamiya M, Deguchi M, et al. Jakudoku munpusu wirusu Torii kabu wakuchin (Takeda) no kaihatsu ni kansuru kenkyu, shisaku wakuchin no rikika to koutai sanseinou no kentou [Study of the development of an attenuated mumps Torii strain vaccine: evaluation of titers and antibody production efficacy of prototype vaccines]. Rinsho to uirusu. 1981;9:331\u20135."},{"key":"10.1016\/j.vaccine.2021.07.097_b0090","unstructured":"Shishido A, Hayami M, Hishiyama M, Isomura S, Kikmura K, Horiuchi K, et al. Jakudoku munpusu wirusu Torii kabu wakuchin (Takeda) no kaihatsu ni kansuru kenkyu, yagai sesshu shiken [Study of the development of an attenuated mumps Torii strain vaccine: field vaccination test]. Rinsho to uirusu. 1981;9:336\u201342."},{"key":"10.1016\/j.vaccine.2021.07.097_b0095","first-page":"245","article-title":"Mashin wakuchin shuwarutsu FF-8 kabu to AIK-C kabu (Hokken) tono hikaku rinshou shiken [Comparative clinical study of measles vaccine of Schwarz FF-8 strain and AIK-C(Hokken)]","volume":"10","author":"Hirayama","year":"1982","journal-title":"Rinsho to uirusu"},{"key":"10.1016\/j.vaccine.2021.07.097_b0100","first-page":"543","article-title":"Jakudoku nama mashin fushin, munpusu sanshu kongou wakuchin (Takeda) no rinshou shiken seiseki [Effectiveness of attenuated live measles-rubella-mumps combinated vaccine (Takeda)]","volume":"15","author":"Hirayama","year":"1987","journal-title":"Rinsho to uirusu"},{"key":"10.1016\/j.vaccine.2021.07.097_b0105","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/S0264-410X(00)00016-5","article-title":"Experience with live attenuated varicella vaccine (Oka strain) in healthy Japanese subjects; 10-year survey at pediatric clinic","volume":"18","author":"Ozaki","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.07.097_b0110","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.vaccine.2004.08.040","article-title":"Safety and immunogenicity of gelatin-free varicella vaccine in epidemiological and serological studies in Japan","volume":"23","author":"Ozaki","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.07.097_b0115","first-page":"693","article-title":"Immunogenicity of two-dose schedule for mumps vaccination","volume":"121","author":"Naoko","year":"2017","journal-title":"J Jpn Pediatr Soc"},{"key":"10.1016\/j.vaccine.2021.07.097_b0120","unstructured":"Measles IgG-EIA. 7 ed. Package Insert. Denka Company Limited; 2020."},{"key":"10.1016\/j.vaccine.2021.07.097_b0125","unstructured":"Rubella IgG-EIA. 6 ed. Package Insert. Denka Company Limited; 2020."},{"key":"10.1016\/j.vaccine.2021.07.097_b0130","unstructured":"Varicella-zoster IgG-EIA. 7 ed. Package Insert. Denka Company Limited; 2020."},{"key":"10.1016\/j.vaccine.2021.07.097_b0135","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1128\/jcm.8.5.545-552.1978","article-title":"Antibody assays for varicella-zoster virus: comparison of enzyme immunoassay with neutralization, immune adherence hemagglutination, and complement fixation","volume":"8","author":"Forghani","year":"1978","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2021.07.097_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-4642(18)30293-1","article-title":"Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study","author":"Miyata","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.vaccine.2021.07.097_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2020.05.034","article-title":"Epidemiology, treatments, and cardiac complications in patients with Kawasaki disease: The Nationwide Survey in Japan, 2017\u20132018","author":"Ae","year":"2020","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2021.07.097_b0150","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00431-003-1335-3","article-title":"Time interval of measles vaccination in patients with Kawasaki disease treated with additional intravenous immune globulin","volume":"163","author":"Miura","year":"2004","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.vaccine.2021.07.097_b0155","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1001\/archpedi.161.3.294","article-title":"Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment","volume":"161","author":"LeBaron","year":"2007","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"217\u201322","key":"10.1016\/j.vaccine.2021.07.097_b0160","article-title":"Prospective study of live attenuated vaccines for patients with nephrotic syndrome receiving immunosuppressive agents","volume":"196","author":"Kamei","year":"2018","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2021.07.097_b0165","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/jmv.1890330311","article-title":"Measles virus specific antibody in infants in a highly vaccinated society","volume":"33","author":"Chui","year":"1991","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2021.07.097_b0170","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jama.1977.03270310031003","article-title":"Measles immunization. Successes and failures","volume":"237","author":"Yeager","year":"1977","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.07.097_b0175","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1542\/peds.93.6.939","article-title":"Measles vaccine immunogenicity in 6- versus 15-month-old infants born to mothers in the measles vaccine era","volume":"93","author":"Johnson","year":"1994","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.07.097_b0180","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jcla.21621","article-title":"Comparison of hemagglutination inhibition assay and enzyme immunoassay for determination of mumps and rubella immune status in health care personnel","volume":"27","author":"Kumakura","year":"2013","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.vaccine.2021.07.097_b0185","doi-asserted-by":"crossref","first-page":"519","DOI":"10.11150\/kansenshogakuzasshi.83.519","article-title":"EIA-IgG antibody measles prevention level estimated from measles neutralizing, particle agglutination and hemagglutination-inhibition antibody titer","volume":"83","author":"Takayama","year":"2009","journal-title":"Kansenshogaku Zasshi"},{"key":"10.1016\/j.vaccine.2021.07.097_b0190","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/S0264-410X(99)00574-5","article-title":"Measles vaccine immunogenicity and antibody persistence in 12 vs 15-month old infants","volume":"18","author":"Johnson","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.07.097_b0195","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0264-410X(98)00083-8","article-title":"Immune response to measles vaccine in 6-month-old infants of measles seronegative mothers","volume":"16","author":"Kumar","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.07.097_b0200","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s10156-011-0358-3","article-title":"Antibodies against mumps virus component proteins","volume":"18","author":"Matsubara","year":"2012","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.vaccine.2021.07.097_b0205","doi-asserted-by":"crossref","first-page":"670","DOI":"10.11150\/kansenshogakuzasshi1970.74.670","article-title":"Comparison of positivity rates for antibodies against measles, rubella, chickenpox and mumps by assays","volume":"74","author":"Terada","year":"2000","journal-title":"Kansenshogaku Zasshi"},{"key":"10.1016\/j.vaccine.2021.07.097_b0210","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00006454-200002000-00003","article-title":"Testing for rubella-specific IgG antibody in urine","volume":"19","author":"Terada","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.07.097_b0215","unstructured":"Japan Pediatric Society, Vaccination Schedule Recommended by the Japan Pediatrics Society."},{"key":"10.1016\/j.vaccine.2021.07.097_b0220","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1016\/j.vaccine.2014.06.022","article-title":"Recent progress and concerns regarding the Japanese immunization program: addressing the \u201cvaccine gap\u201d","volume":"32","author":"Saitoh","year":"2014","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21010112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21010112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:00:02Z","timestamp":1759402802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21010112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":44,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0264410X21010112"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.07.097","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Live attenuated vaccine efficacy six months after intravenous immunoglobulin therapy for Kawasaki disease","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.07.097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}